Similar Items: Lecanemab treatment modulates brain volume and cerebrospinal fluid pathways in early Alzheimer's disease: Insights from longitudinal magnetic resonance imaging
- Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment
- Real‐world use of lecanemab: patient pathway findings from a US multicenter study
- From clinical trial to clinical experience: Lecanemab therapy in a real‐world case series
- Lecanemab and amyloid‐related imaging abnormalities: Real‐world data from a single center experience
- Alzheimer's disease drug development pipeline: 2026
- Interchangeability of CSF and PET to identify Alzheimer's disease pathology